Company Description
Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications.
The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.
The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.
Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
| Country | United States |
| IPO Date | Jan 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Chun-Hsien Tsai |
Contact Details
Address: 8880 Rio San Diego Drive San Diego, California United States | |
| Website | https://ainos.com |
Stock Details
| Ticker Symbol | AIMD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001014763 |
| CUSIP Number | 00902F105 |
| ISIN Number | US00902F3038 |
| Employer ID | 75-1974352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chun-Hsien Tsai | Chairman of Board, President & Chief Executive Officer |
| Hsin-Liang Lee | Chief Financial Officer |
| Chih-Heng Lu | Director of Corporate Developoment |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | S-3/A | [Amend] Filing |
| Dec 23, 2024 | S-3 | Filing |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 27, 2024 | SC 13D/A | [Amend] Filing |
| Nov 15, 2024 | 4 | Filing |
| Nov 15, 2024 | 4 | Filing |